Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 24, 2009, Pages 2519-2529

  Teunissen, S F ^a   Rosing, H ^a   Koornstra, R H T ^a   Linn, S C ^a   Schellens, J H M ^a   Schinkel, A H ^a   Beijnen, J H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Endoxifen; Flavonoids; Liquid chromatography; Metabolites; Tamoxifen; Tandem mass spectrometry

Indexed keywords

ALTERNATIVE MEDICINE; BIOANALYTICAL ASSAYS; BREAST CANCER; DAIDZEIN; DIETARY SUPPLEMENTS; ENDOXIFEN; FLAVONOID; FLAVONOIDS; GENISTEIN; GLYCITEIN; HUMAN SERUM; IN-VIVO; LINEAR RANGE; MULTIPLE REACTION MONITORING; POSITIVE ION MODE; PROTEIN PRECIPITATION; QUANTITATIVE ASSAY; REVERSED PHASE LIQUID-CHROMATOGRAPHY; SAMPLE PRETREATMENT; SERUM CONCENTRATION; SIMULTANEOUS ANALYSIS; TAMOXIFEN; TANDEM MASS SPECTROMETRY;

ACETONITRILE; BIOMOLECULES; BODY FLUIDS; CHROMATOGRAPHIC ANALYSIS; CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETERS; MASS SPECTROMETRY; METABOLISM; METABOLITES; PRECIPITATION (CHEMICAL);

HIGH PRESSURE LIQUID CHROMATOGRAPHY;

ACETONITRILE; DAIDZEIN; FLAVANOID; GENISTEIN; GLYCITEIN; TAMOXIFEN;

ARTICLE; BLOOD SAMPLING; BREAST CANCER; DRUG BLOOD LEVEL; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VIVO STUDY; PRIORITY JOURNAL; QUANTITATIVE ASSAY; REVERSED PHASE LIQUID CHROMATOGRAPHY; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; HUMANS; ISOFLAVONES; NEOPLASMS; TAMOXIFEN; TANDEM MASS SPECTROMETRY;

EID: 67650713316     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.06.029     Document Type: Article

References (34)

1. Jordan V.C. Steroids 72 (2007) 829
2. Schwartz J. Front. Biosci. 9 (2004) 2827
3. Lim Y.C., Desta Z., Flockhart D.A., and Skaar T.C. Cancer Chemother. Pharmacol. 55 (2005) 471
4. Coezy E., Borgna J.L., and Rochefort H. Cancer Res. 42 (1982) 317
5. Katzenellenbogen B.S., Norman M.J., Eckert R.L., Peltz S.W., and Mangel W.F. Cancer Res. 44 (1984) 112
6. Johnson M.D., Zuo H., Lee K.H., Trebley J.P., Rae J.M., Weatherman R.V., Desta Z., Flockhart D.A., and Skaar T.C. Breast Cancer Res. Treat. 85 (2004) 151
7. Wu X., Hawse J.R., Subramaniam M., Goetz M.P., Ingle J.N., and Spelsberg T.C. Cancer Res. 69 (2009) 1722
8. Stearns V., Johnson M.D., Rae J.M., Morocho A., Novielli A., Bhargava P., Hayes D.F., Desta Z., and Flockhart D.A. J. Natl. Cancer Inst. 95 (2003) 1758
9. Jin Y., Desta Z., Stearns V., Ward B., Ho H., Lee K.H., Skaar T., Storniolo A.M., Li L., Araba A., Blanchard R., Nguyen A., Ullmer L., Hayden J., Lemler S., Weinshilboum R.M., Rae J.M., Hayes D.F., and Flockhart D.A. J. Natl. Cancer Inst. 97 (2005) 30
10. Borges S., Desta Z., Li L., Skaar T.C., Ward B.A., Nguyen A., Jin Y., Storniolo A.M., Nikoloff D.M., Wu L., Hillman G., Hayes D.F., Stearns V., and Flockhart D.A. Clin. Pharmacol. Ther. 80 (2006) 61
11. Kupfer D., and Dehal S.S. Methods Enzymol. 272 (1996) 152
12. Parte P., and Kupfer D. Drug Metab. Dispos. 33 (2005) 1446
13. Bates D.J., Foster A.B., Griggs L.J., Jarman M., Leclercq G., and Devleeshouwer N. Biochem. Pharmacol. 31 (1982) 2823
14. Vaya J., and Tamir S. Curr. Med. Chem. 11 (2004) 1333
15. Newton K.M., Buist D.S., Keenan N.L., Anderson L.A., and LaCroix A.Z. Obstet. Gynecol. 100 (2002) 18
16. Wong M.C., Emery P.W., Preedy V.R., and Wiseman H. Inflammopharmacology 16 (2008) 235-239
17. Chen J., Halls S.C., Alfaro J.F., Zhou Z., and Hu M. Pharm. Res. 21 (2004) 2095
18. Okada H., Tokunaga T., Liu X., Takayanagi S., Matsushima A., and Shimohigashi Y. Environ. Health Perspect. 116 (2008) 32
19. Helferich W.G., Andrade J.E., and Hoagland M.S. Inflammopharmacology 16 (2008) 219-226
20. Guha N., Kwan M.L., Quesenberry Jr. C.P., Weltzien E.K., Castillo A.L., and Caan B.J. Breast Cancer Res Treat. (2009) [Epub ahead of print]
21. Fried K.M., and Wainer I.W. J. Chromatogr. B: Biomed. Appl. 655 (1994) 261
22. Gjerde J., Kisanga E.R., Hauglid M., Holm P.I., Mellgren G., and Lien E.A. J. Chromatogr. A 1082 (2005) 6
23. Kikuta C., and Schmid R. J. Pharm. Biomed. Anal. 7 (1989) 329
24. Lee K.H., Ward B.A., Desta Z., Flockhart D.A., and Jones D.R. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 791 (2003) 245
25. Zhu Y.B., Zhang Q., Zou J.J., Yu C.X., and Xiao D.W. J. Pharm. Biomed. Anal. 46 (2008) 349
26. Grace P.B., Mistry N.S., Carter M.H., Leathem A.J., and Teale P. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 853 (2007) 138
27. Prasain J.K., and Barnes S. Mol. Pharm. 4 (2007) 846
28. de Rijke E., Out P., Niessen W.M., Ariese F., Gooijer C., and Brinkman U.A. J. Chromatogr. A 1112 (2006) 31
29. Williams L.D., Twaddle N.C., Churchwell M.I., and Doerge D.R. J. AOAC Int. 89 (2006) 1168
30. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry Bioanalytical Method Validation, 2008, http://www.fda.gov/CDER/GUIDANCE/4252fnl.pdf.
31. Zheng Y., Sun D., Sharma A.K., Chen G., Amin S., and Lazarus P. Drug Metab. Dispos. 35 (2007) 1942
32. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Chemistry Review(s), 2008, http://www.fda.gov/cder/foi/nda/2005/021807s000_ChemR.pdf.
33. Lough W.J., and Wainer I.W. High-Performance Liquid Chromatography: Fundamental Principles and Practice. 1 edition (1995), Springer
34. Kang J., Hick L.A., and Price W.E. Rapid Commun. Mass Spectrom. 21 (2007) 857